News · Funding Round
Biotech Connecta Therapeutics raises €3.1 million in a round led by Clave Capital
Venture Map Series A · €3.1MCONNECTA Therapeutics1 outlet ShowHide
The round
Round page →
CONNECTA TherapeuticsSeries A
€3.1M
Led by
With 3
Inveready, CDTI Innvierte, Prous Institute for Biomedical Research
Biotech · CNS therapeutics
In this story 1
Coverage 1
- VIA EmpresaOriginal on VIA Empresa (opens in a new tab) 10 Sep
The story so far, in brief; the legwork, and the full article, stay with the original outlet.
Connecta Therapeutics has closed a €3.1 million round led by Clave Capital, a new investor, through its Innvierte Science Tech Clave Innohealth fund. Inveready, DCTI Innvierte and Prous Institute for Biomedical Research, already shareholders, came back for more.
The money funds CTH120, a drug for adult men with Fragile X syndrome, in phase IIa trials since June. Clave's Ignacio Prieto Fernández gets a board seat.